The Effect of Quisinostat as the HDAC Inhibitor on Migration

Background and Aim: Cancer cannot be explained only by genetic alterations but involves epigenetic processes. Modifying histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between Histone Deacetylases (HDAC) and Histone Acetyltransfer...

Full description

Bibliographic Details
Main Authors: Marjan Hajimoradi Javarsiani, Javad Sajedianfard, Shagayegh Haghjooy Javanmard
Format: Article
Language:fas
Published: Arak Medical University 2021-08-01
Series:Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk
Subjects:
Online Access:http://jams.arakmu.ac.ir/article-1-6668-en.html
_version_ 1818157117597548544
author Marjan Hajimoradi Javarsiani
Javad Sajedianfard
Shagayegh Haghjooy Javanmard
author_facet Marjan Hajimoradi Javarsiani
Javad Sajedianfard
Shagayegh Haghjooy Javanmard
author_sort Marjan Hajimoradi Javarsiani
collection DOAJ
description Background and Aim: Cancer cannot be explained only by genetic alterations but involves epigenetic processes. Modifying histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between Histone Deacetylases (HDAC) and Histone Acetyltransferases (HAT). The HDACs expression and activity could be involved in several tumorigenesis mechanisms, so their inhibition induces cancer cell cycle arrest and migration. Methods & Materials: Quisinostat is a novel promising second-generation HDAC inhibitor class of hydroxamic acid with high cellular potency towards classes I and II HDACs. Therefore, its low IC50 (<0.5nM) and bioavailability have been chosen to carry out our studies. Cancer cells were treated with Quiznos at nM200, and cell migration was measured by fluorescent microscopy. Ethical Considerations: This study was the result of a preliminary study of Shiraz University (Code: 96GCU3M1293). Results: The data showed that treatment of cancer cells with Quiznos significantly (P<0.05) reduced cell migration. DMSO did not affect reducing cell migration. Conclusion: In this project try to explore the possible therapeutic application of this HDAC inhibitor against colon cancer. This study showed Quisinostat exerts broad-spectrum antiproliferative activity and migration.
first_indexed 2024-12-11T15:09:06Z
format Article
id doaj.art-7002831d159b4e04978c5392d1651ced
institution Directory Open Access Journal
issn 1735-5338
2008-644X
language fas
last_indexed 2024-12-11T15:09:06Z
publishDate 2021-08-01
publisher Arak Medical University
record_format Article
series Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk
spelling doaj.art-7002831d159b4e04978c5392d1651ced2022-12-22T01:00:48ZfasArak Medical UniversityMajallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk1735-53382008-644X2021-08-01243450457The Effect of Quisinostat as the HDAC Inhibitor on MigrationMarjan Hajimoradi Javarsiani0Javad Sajedianfard1Shagayegh Haghjooy Javanmard2 Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran. Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. Background and Aim: Cancer cannot be explained only by genetic alterations but involves epigenetic processes. Modifying histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between Histone Deacetylases (HDAC) and Histone Acetyltransferases (HAT). The HDACs expression and activity could be involved in several tumorigenesis mechanisms, so their inhibition induces cancer cell cycle arrest and migration. Methods & Materials: Quisinostat is a novel promising second-generation HDAC inhibitor class of hydroxamic acid with high cellular potency towards classes I and II HDACs. Therefore, its low IC50 (<0.5nM) and bioavailability have been chosen to carry out our studies. Cancer cells were treated with Quiznos at nM200, and cell migration was measured by fluorescent microscopy. Ethical Considerations: This study was the result of a preliminary study of Shiraz University (Code: 96GCU3M1293). Results: The data showed that treatment of cancer cells with Quiznos significantly (P<0.05) reduced cell migration. DMSO did not affect reducing cell migration. Conclusion: In this project try to explore the possible therapeutic application of this HDAC inhibitor against colon cancer. This study showed Quisinostat exerts broad-spectrum antiproliferative activity and migration.http://jams.arakmu.ac.ir/article-1-6668-en.htmlhdacquisinostatcancer cellsmigration
spellingShingle Marjan Hajimoradi Javarsiani
Javad Sajedianfard
Shagayegh Haghjooy Javanmard
The Effect of Quisinostat as the HDAC Inhibitor on Migration
Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk
hdac
quisinostat
cancer cells
migration
title The Effect of Quisinostat as the HDAC Inhibitor on Migration
title_full The Effect of Quisinostat as the HDAC Inhibitor on Migration
title_fullStr The Effect of Quisinostat as the HDAC Inhibitor on Migration
title_full_unstemmed The Effect of Quisinostat as the HDAC Inhibitor on Migration
title_short The Effect of Quisinostat as the HDAC Inhibitor on Migration
title_sort effect of quisinostat as the hdac inhibitor on migration
topic hdac
quisinostat
cancer cells
migration
url http://jams.arakmu.ac.ir/article-1-6668-en.html
work_keys_str_mv AT marjanhajimoradijavarsiani theeffectofquisinostatasthehdacinhibitoronmigration
AT javadsajedianfard theeffectofquisinostatasthehdacinhibitoronmigration
AT shagayeghhaghjooyjavanmard theeffectofquisinostatasthehdacinhibitoronmigration
AT marjanhajimoradijavarsiani effectofquisinostatasthehdacinhibitoronmigration
AT javadsajedianfard effectofquisinostatasthehdacinhibitoronmigration
AT shagayeghhaghjooyjavanmard effectofquisinostatasthehdacinhibitoronmigration